IMNM
Immunome, Inc.
$17.99
-1.48%
2026-10-23
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Key Fundamentals
Forward P/E
-8.82
EPS (TTM)
$-2.53
ROE
-64.0%
Revenue Growth (YoY)
-100.0%
Profit Margin
0.0%
Debt/Equity
0.90
Price/Book
4.62
Beta
2.13
Market Cap
$2.43B
Avg Volume (10D)
1.6M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$30.06
60D Low
$16.41
Avg Volume
1.3M
Latest Close
$17.99
Get breakout alerts for IMNM
Sign up for Breakout Scanner to receive daily notifications when IMNM triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Immunome, Inc. (IMNM) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IMNM daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IMNM operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.